
 
 
 
 
 
 
 
 
 What is claimed is:  
   
 1. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the MuSK-activating C-terminal fragment (portion) of human agrin, wherein the nucleotide sequence is selected from: 
 (a) nucleotide sequence comprising the coding region of the MuSK-activating C-terminal fragment (portion) of human agrin contained in the vector designated as pBL-hAgrin 1 American Type Culture Collection Accession No. 97378);  
 (b) a nucleotide sequence whose complement hybridizes under stringent conditions of:  
 0.15 NaCl/0.015 sodium citrate/0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM sodium citrate at 42째 C. and a final wash step of 65째 C. to the nucleotide sequence of (a) and which encodes the MuSK-activating C-terminal fragment (portion) of human agrin; or  
 (c) a nucleotide sequence that, as a result of the degeneracy of the genetic code, differs from the nucleotide sequence of (a) or (b) and which encodes the MuSK-activating C-terminal fragment (portion) of human agrin.  
 
     
 2. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the MuSK-activating C-terminal fragment (portion) of human agrin, wherein the nucleotide sequence is selected from the group consisting of: 
 (a) the nucleotide sequence as set forth in SEQ ID NO 35;  
 (b) the nucleotide sequence encoding amino acids 24 to 492 as set forth in SEQ ID NO: 36;  
 (c) the nucleotide sequence encoding amino acids 60 to 492 as set forth in SEQ ID NO: 36;  
 (d) the nucleotide sequence encoding amino acids 76 to 492 as set forth in SEQ ID NO: 36;  
 (e) the nucleotide sequence encoding amino acids 126 to 492 as set forth in SEQ ID NO: 36;  
 (f) the nucleotide sequence encoding amino acids 178 to 492 as set forth in SEQ ID NO: 36;  
 (g) the nucleotide sequence encoding amino acids 222 to 492 as set forth in SEQ ID NO: 36;  
 (h) the nucleotide sequence encoding amino acids 260 to 492 as set forth in SEQ ID NO: 36;  
 (i) the nucleotide sequence encoding amino acids 300 to 492 as set forth in SEQ ID NO: 36;  
 (j) a nucleotide sequence whose complement hybridizes under stringent conditions of:  
 0.15 NaCl/0.015 sodium citrate/0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM sodium citrate at 42째 C. and a final wash step of 65째 C. to any of the nucleotide sequences of (a) through (i) and which encodes the MuSK-activating C-terminal fragment (portion) of human agrin; and  
 (k) a nucleotide sequence that, as a result of the degeneracy of the genetic code, differs from any of the nucleotide sequences of (a)-(j) and which encodes the MuSK-activating C-terminal fragment (portion) of human agrin.  
 
     
 3. An isolated nucleic acid molecule of  claim 1  which is lacking an insert at position Y. 
 
     
 4. An isolated nucleic acid molecule of  claim 2 , which is lacking an insert at position Y. 
 
     
 5. An isolated nucleic acid molecule of  claim 1  which is lacking an insert at position Z. 
 
     
 6. An isolated nucleic acid molecule of  claim 2 , which is lacking an insert at position Z. 
 
     
 7. An isolated polypeptide encoded by the nucleic acid molecule of  claim 1 ,  2 ,  3 ,  4 ,  5  or  6 . 
 
     
 8. A polypeptide of  claim 7 , modified by covalent attachment of a polyethylene glycol molecule. 
 
     
 9. A vector which comprises the isolated nucleic acid molecule of  claim 1 ,  2 ,  3 ,  4 ,  5  or  6 . 
 
     
 10. An expression vector comprising a nucleic acid molecule of  claim 1 ,  2 ,  3 ,  4 ,  5  or  6  wherein the nucleic acid molecule is operatively linked to an expression control sequence. 
 
     
 11. A composition comprising a polypeptide as defined in  claim 7  and a carrier. 
 
     
 12. A host cell transformed with the expression vector of  claim 10 . 
 
     
 13. The transformed host cell of  claim 12 , Wherein said cell is selected from the group consisting of: a bacterial cell, a yeast cell, an insect cell, and a mammalian cell. 
 
     
 14. A method of producing a polypeptide having the MuSK-activating property of human agrin, wherein said method comprises growing the transformed host cell of  claim 12  under conditions permitting production of the polypeptide and recovering the polypeptide so produced. 
 
   
 
 
 
 
 
 
 
 
